Antech Diagnostics and PetDx Expand Access to OncoK9, the Multi-Cancer Early Detection Test for Dogs
The strategic relationship announced today makes OncoK9 immediately available to all Antech customers in the United States and Canada
PetDx to Present at Stifel 2022 Jaws & Paws Conference
PetDx® – The Liquid Biopsy Company for Pets™ is participating in the Stifel 2022 Jaws & Paws Conference taking place in New York City on Wednesday, June 1, 2022. PetDx Founder and CEO Daniel S. […]
PetDx Announces Publication of Landmark Clinical Validation Study for OncoK9, Its Pioneering Multi-Cancer Early Detection Test for Dogs Using Next-Generation Sequencing
Published in PLOS ONE, the CANcer Detection in Dogs (CANDiD) study–the largest clinical validation study in veterinary cancer diagnostics–sets a new benchmark for veterinary medicine
Veterinarians Using OncoK9 Liquid Biopsy Test in Complex Clinical Cases Can Consult with Specialists Through the Fidu Telemedicine Platform
Access to Internal Medicine and Oncology Consultations Will Support Veterinarians Prescribing First-in-Class Multi-Cancer Early Detection (MCED) Test from PetDx®
PetDx and IDEXX Expand Access to OncoK9, the Cancer Liquid Biopsy Test for Dogs
The collaborative effort makes OncoK9 available immediately to veterinary customers served by IDEXX Reference Laboratories
PetDx Raises $62 Million in Series B Financing to Scale Adoption of its Canine Multi-Cancer Early Detection Blood Test, OncoK9
OncoK9® is a first-in-class multi-cancer early detection (MCED) test that employs next-generation sequencing (NGS) to detect many types of cancer in dogs with a simple blood draw.
PetDx launches OncoK9, a pioneering blood-based multi-cancer early detection (MCED) test for dogs
OncoK9 Initially Available at Select Petco Full-Service Veterinary Hospitals Beginning in May